NCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
Clinical Trials
3 trialsNCT05271916 2023-04-19
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT01116843 2015-07-10
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
University Health Network, Toronto
Phase 1/2 Completed